PENSACOLA, FL, USA, January 30, 2025/ Farcast Biosciences, a pioneer and leader in human tumor microdynamics research, today announced a name change to Farcast Biodynamics. This reflects the company’s commitment to advancing its tumor microenvironment (TME) technology to a comprehensive dynamic system that incorporates TME perturbation signals, TME peripheral signals from blood draws, and its biosignature computation model. The Farcast system positions the company for new breakthroughs in drug development through preclinical and clinical programs, as well as in liquid biopsy based clinical diagnostics.

Farcast’s TME research has already yielded biosignatures to accurately estimate response and prognosis that have been published in Nature Communications and Cancer Immunology Research. Integrating data from core and peripheral components, and longitudinal treatment results, Farcast biosignatures will now achieve even higher power in predicting clinical response across a wide range of therapies and cancer types. The system's integration of multimodal signals from the TME and its peripheral components has the power to reshape response rates for cancer patients.

“This evolution represents an exciting new chapter in our journey,” said Mohit Malhotra, CEO. “Farcast Biodynamics truely conveys the transformative impact we aim to achieve in making precision cancer medicine work better for patients. We believe that none of the existing approaches based on organoids/tumoroids, 2D/3D cultures, CTC or ctDNA  capture the entire range of TME signals from tissue or blood samples. The Farcast biodynamics system has many applications in drug development and in guiding the entire patient treatment trajectory.”

While the company’s name has changed, its dedication to excellence and its mission to make precision cancer medicine work better, remain unwavering. Farcast Biodynamics will continue to execute on its research activities, commercial programs and partnerships, and growth plans just as before.